Medicine pack check sheet

Source-linked reading points

• Check Catapres-TTS, clonidine transdermal system, -1/-2/-3, weekly use and the 0.1/0.2/0.3 mg-per-day label information as one product-identity set. These identify the exact system; they are not self-conversion rules for adding, cutting, layering, replacing or changing to oral clonidine.
• The FDA label describes a multilayer system with a rate-controlling membrane. A loose-looking system, a change in appearance or a feeling that it is “not enough” cannot be used to infer cutting, enlarging the area, adding another system or changing use; have the exact package reviewed by a pharmacist or prescribing team.
• Sharing clonidine or a blood-pressure context does not prove that a patch, an oral form or another antihypertensive can be self-combined, substituted or suddenly stopped. With a beta blocker, certain calcium-channel blockers, sedating medicines, alcohol or other chronic-care products, have professionals review the complete list and actual products.
• For marked redness, blistering or widespread rash at the application site, dizziness, fainting, symptoms related to an abnormal heart rate, or uncertainty about a patch around MRI, surgery or another special situation, use timely local medical and professional support; this page does not provide an application, removal or discontinuation plan.